Adma Biologics reported $134.22M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Adma Biologics USD 134.22M 12.24M Sep/2025
Alnylam Pharmaceuticals USD 1.25B 476.31M Sep/2025
Dynavax Technologies USD 94.9M 540K Sep/2025
Takeda JPY 1.19T 80B Dec/2025